Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B

NCT01926288 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 287

Last updated 2017-12-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Entecavir maleate tablets in Chinese patients with hepatitis B

Conditions

Interventions

DRUG

Entecavir maleate tablets

DRUG

blank Baraclude tablets

DRUG

Blank maleate entecavir tablets

DRUG

Baraclude tablets

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yu Yan yan, doctor · Department of Infectious Diseases,Peking University First Hospital

  • Shi Guang feng, doctor · Huashan Hospital

  • Xie Qing, doctor · Shanghai Jiaotong University Affiliated Ruijin Hospital

  • Tang Hong, doctor · West China Hospital

  • Zhang Da zhi, doctor · The Second Affiliated Hospital of Chongqing Medical University

  • Mao Qing, doctor · The First Affiliated Hospital Of The Third Mililary Medical University

  • Ning Qin, doctor · Tongji Medical College of Hust Tongji Medical College Huazhong University of Science and Technology

  • Li Jun, doctor · The First Affiliated Hospital with Nanjing Medical University

  • Sheng Ji fang, doctor · Zhejiang University

  • Cheng Xin fang, doctor · Beijing You An Hospital,Capital Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01926288 on ClinicalTrials.gov